Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.68 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.68 |
| ▸ | VEGFA | P15692 | 3/20 | 0.68 |
| ▸ | FLT1 | P17948 | 3/20 | 0.68 |
| ▸ | TET3 | O43151 | 1/20 | 0.68 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.68 |
| ▸ | ASPH | Q12797 | 1/20 | 0.68 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.68 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.68 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.68 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.68 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514566 | 1.00 | EGLN1 (0.68) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921043 | 0.91 | EGLN1 (0.65) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921394 | 0.90 | EGLN1 (0.64) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL19935708 | 0.87 | EGLN1 (0.60) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921397 | 0.87 | EGLN1 (0.60) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL3031405 | 0.87 | EGLN1 (0.63) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL30346108 | 0.87 | EGLN1 (0.63) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL3031409 | 0.87 | EGLN1 (0.63) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL19393710 | 0.87 | EGLN1 (0.63) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL23501777 | 0.86 | EGLN1 (0.55) | EGLN1EGLN3VEGFAFLT1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-01-05 | — | — | US | claimed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | claimed |
| EP-3683209-B1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | AKEBIA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | claimed |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-04-29 | — | — | US | claimed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| EP-2044005-B8 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2012-12-05 | — | — | EP | claimed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-20250243164-A1 | PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACID | AKEBIA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269802-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid | AKEBIA THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4448493-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | EGLN1 140/4885EGLN3 12/4885VEGFA 3903/4885 |
| US-20250243164-A1 | PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACID | AASDHPPT, AADAT, HPD | EGLN1 2838/4885EGLN3 1309/4885VEGFA 3354/4885 |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | HPD, APEH, P4HA1 | EGLN1 140/4885EGLN3 12/4885VEGFA 3903/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | EGLN1 140/4885EGLN3 12/4885VEGFA 3903/4885 |
| US-12269802-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid | AASDHPPT, AADAT, ALDH7A1 | EGLN1 2285/4885EGLN3 932/4885VEGFA 2569/4885 |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN1, EGLN2 | EGLN1 2/4885EGLN3 4/4885VEGFA 4159/4885 |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, ALDH7A1 | EGLN1 131/4885EGLN3 18/4885VEGFA 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.